Divine Aleru, Microbiome Signatures Research Coordinator

This review highlights lactoferrin’s immunomodulatory role in shaping innate and adaptive responses, with significant implications for neonatal health, microbial defense, and inflammation control. It underlines lactoferrin’s microbiome relevance and clinical potential as a natural immune support agent.

Lactoferrin is a key immunomodulatory glycoprotein that bridges innate and adaptive immunity. It regulates oxidative stress, curbs inflammation, and supports mucosal immune integrity, showing promise for microbiome-focused interventions in infections, SIRS, and immune dysfunction.

This review highlights lactoferrin’s role as a biomarker for IBD, AD, and DED, and evaluates current detection technologies. It emphasizes LF’s dual function in host defense and microbiome support.

This review explores lactoferrin’s biological roles, from microbiome modulation and immune defense to chronic disease and cancer prevention, supporting its use as a multifunctional therapeutic.

This review explores lactoferrin’s multifaceted biological roles, emphasizing its ability to shape the microbiome, support immunity, and suppress inflammation and tumors.

This review explores lactoferrin’s protective, antimicrobial, and immunomodulatory roles across life stages, highlighting its impact on the gut microbiome, disease prevention, and aging-related health.

This study confirms secnidazole’s efficacy and safety as a one-dose treatment for BV, improving outcomes while supporting microbiome restoration.

This study assessed vaginal microbiota in BV-positive women using real-time PCR. It found reduced Lactobacillus crispatus, biofilm-associated pathogens, and high diagnostic accuracy for molecular testing. Results suggest PCR-based diagnostics improve BV detection and highlight the need for microbiome-targeted therapies.

This study examines vaginal microbiome recovery after metronidazole treatment for BV. Findings show delayed microbiota stabilization, L. iners dominance post-treatment, and the need for improved diagnostic tools to predict BV recurrence.

This study compares the microbiological effects of metronidazole and clindamycin in treating bacterial vaginosis, highlighting differences in antimicrobial resistance and efficacy in eliminating BV-associated pathogens.

This review assesses the use of tinidazole for treating bacterial vaginosis, comparing its efficacy, side effects, and cost to metronidazole. It highlights tinidazole’s favorable side effect profile and its role in treating recurrent BV.

This review explores the role of vaginal microbiota in bacterial vaginosis and highlights emerging microbiome-informed treatments. It emphasizes microbial signatures of BV, the limitations of antibiotics, and the potential of targeted biotherapeutics to restore microbial balance and reduce recurrence.

This review explains how microbial shifts, metabolite production, and immune responses interact in bacterial vaginosis. It highlights the roles of Gardnerella, Atopobium, and other anaerobes in disrupting vaginal health and discusses how their metabolic byproducts and immune modulation drive BV symptoms and persistence.

This review explores bacterial vaginosis, focusing on microbial imbalances, immune responses, and diagnostic challenges. It highlights the need for microbiome-based treatments and improved diagnostics to reduce recurrence and improve BV management.

This study evaluates the efficacy and safety of a single-dose 2% clindamycin vaginal gel for treating bacterial vaginosis, demonstrating significant clinical and bacteriologic cure rates compared to a placebo.

This systematic review analyzed six trials evaluating secnidazole for bacterial vaginosis treatment. Secnidazole at 2 g significantly improved clinical and microbiologic cure rates, showing comparable efficacy to metronidazole. The single-dose regimen enhances adherence, offering an alternative for patients with recurrent BV or adverse effects from standard therapies.

This study evaluated a Saccharomyces cerevisiae-based probiotic for bacterial vaginosis treatment. The probiotic selectively inhibited BV-associated pathogens like G. vaginalis without harming beneficial lactobacilli, offering a microbiome-friendly alternative to antibiotics.

This study links high pre-treatment vaginal microbiota diversity to BV recurrence after metronidazole. Women with sustained clearance had lower richness. Lactobacillus iners improved immune markers temporarily, but no cases achieved L. crispatus dominance. Biofilm-forming taxa like Atopobium persisted, suggesting resistance mechanisms.

This meta-analysis reviewed 12 randomized controlled trials and found that probiotics significantly improve the clinical cure rate of bacterial vaginosis. Probiotic use restored beneficial Lactobacillus populations and reduced pathogenic bacteria, highlighting their potential as an effective treatment option and adjunct therapy alongside antibiotics.

This study explores the impact of prebiotic maltose gel on the vaginal microbiota of rhesus macaques, showing its potential to shift microbial balance from BV-related bacteria to Lactobacillus dominance, presenting an alternative to antibiotic treatments for bacterial vaginosis.

This review explores the competing hypotheses behind bacterial vaginosis (BV), emphasizing microbial shifts, racial disparities, and sexual transmission. Key findings suggest BV may be sexually transmitted and driven by Gardnerella vaginalis biofilms, necessitating novel treatment strategies beyond standard antibiotics. Understanding BV pathogenesis is essential for improving prevention and care.

This study highlights metabolic interactions between Gardnerella vaginalis and Prevotella bivia, revealing their role in bacterial vaginosis and preterm birth risk. Using NMR metabolomics, it identifies acetate as a key metabolite linked to vaginal dysbiosis, offering insights for improving BV diagnostics and potential microbiome-targeted interventions.

This study revealed how bacterial vaginosis alters vaginal metabolism, linking specific microbial shifts with distinctive metabolite profiles. It showed that BV-associated bacteria drive metabolic changes that increase vaginal pH, disrupt epithelial integrity, and produce characteristic symptoms, offering new diagnostic markers and therapeutic targets.

This study assesses the impact of metronidazole on the vaginal microbiota, revealing that high G. vaginalis and pathobionts correlate with treatment failure, suggesting a need for biofilm-disrupting therapies in some BV patients.